Rapid Communications in Mass Spectrometry · 2010 · 21 citations · 10 references
PharmacyPharmaceutical AnalysisAnalytical ToxicologyChromatographic AnalysisMass Spectrometric AnalysisBioanalytical Method ValidationMass SpectrometryMetabolite IdentificationMetabolite ProfilingMetabolite QuantificationConcentrationLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisMass Spectrometric DetectionMass Spectrometric QuantificationNeutral Loss AnalysisReference Mass StandardsReference Standards
Different liquid chromatographic/tandem mass spectrometric (LC/MS/MS) scanning techniques were considered for the characterization of tamoxifene metabolites in human urine for anti-doping purpose. Five different LC/MS/MS scanning methods based on precursor ion scan (precursor ion scan of m/z 166, 152 and 129) and neutral loss scan (neutral loss of 72 Da and 58 Da) in positive ion mode were assessed to recognize common ions or common losses of tamoxifene metabolites. The applicability of these methods was checked first by infusion and then by the injection of solution of a mixture of reference standards of four tamoxifene metabolites available in our laboratory. The data obtained by the analyses of the mixture of the reference standards showed that the five methods used exhibited satisfactory results for all tamoxifene metabolites considered at a concentration level of 100 ng/mL, whereas the analysis of blank urine samples spiked with the same tamoxifene metabolites at the same concentration showed that the neutral loss scan of 58 Da lacked sufficient specificity and sensitivity. The limit of detection in urine of the compounds studied was in the concentration range 10-100 ng/mL, depending on the compound structure and on the selected product ion. The suitability of these approaches was checked by the analysis of urine samples collected after the administration of a single dose of 20 mg of tamoxifene. Six metabolites were detected: 4-hydroxytamoxifene, 3,4-dihydroxytamoxifene, 3-hydroxy-4-methoxytamoxifene, N-demethyl-4-hydroxytamoxifene, tamoxifene-N-oxide and N-demethyl-3-hydroxy-4-methoxytamoxifene, which is in conformity to our previous work using a time-of-flight (TOF) mass spectrometer in full scan acquisition mode.
10
Recent Advances in Doping Analysis
Thomas Bassindale, David Cowan, Sara E. C. Dale et al. · 2002 · 547 citations
CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Shangara S. Dehal, David Kupfer · PubMed · 1997 · 188 citations
Medicine, Biochemistry, Pharmacology +17